Latest news with #RoyalPhilips
The Star
4 days ago
- Business
- The Star
Global companies bullish on Chinese market's prospects
Foreign companies, especially those in Europe, are showing growing confidence in China's market potential, as the country's latest economic data underscores a steady recovery in consumption and industrial activity, reaffirming China's appeal as an engine of global growth. World business leaders expressed strong optimism about growth prospects in China, pointing to its vast consumer market, robust investment options in manufacturing and rising innovation capacity as key drivers of new development opportunities for multinational corporations based in Europe and beyond. They reaffirmed their long-term commitment to the Chinese market with plans to further expand investment in the world's second-largest economy, saying that China's steady economic momentum signals long-term potential and broader space for future growth. "China's vast and robust consumer market offers multinational corporations many opportunities, fueled by diversified demand drivers and significant growth potential," said James Zhou, chief commercial officer of Louis Dreyfus Co, a global agribusiness group based in the Netherlands. Roy Jakobs, CEO of Dutch multinational health technology company Royal Philips, also noted signs of stabilization in the Chinese economy, supported by the recovery in consumer activity. "We see consumer confidence and consumer spending rising, which is really encouraging," he said. According to data from the National Bureau of Statistics, China's retail sales grew 6.4 percent year-on-year in May, compared with a 5.1 percent rise in April, making it the fastest pace of growth since late 2023. Despite global uncertainties and rising geopolitical tensions, Jakobs said that Philips remains optimistic about China's prospects, betting on opportunities arising from the country's aging population, continued healthcare reform and rapidly advancing digital ecosystem to drive sustainable business growth. "In the mid- to long-term, we have a very strong outlook on China. We believe China will still be an important driver of global GDP," he said, adding that his company will strengthen its innovation hubs and establish a new one in Beijing. Malu Nachreiner, head of the Region Asia for the Crop Science Division of Bayer, said the Germany-based life sciences enterprise sees promising long-term growth prospects in the Chinese economy. China's steady economic growth indicates great potential for development, thereby providing foreign companies such as Bayer a broader scope for growth in the Chinese market, she said. In early 2025, Bayer launched a new supply center in Hangzhou, Zhejiang province, with an investment of 40 million euros ($46 million). "We are committed to continuing our investments, as we look forward to the opportunities that will arise as the market further opens up," Nachreiner added. French industrial software company Dassault Systemes also reaffirmed its strong commitment to the Chinese market. The company "benefits from China's high-quality development, with the demand driven by digital transformation presenting new opportunities for future business growth", said Zhang Ying, managing director of Dassault Systemes Greater China. Dassault Systemes has established innovation centers in seven cities, including Chongqing, Changchun in Jilin province, and Qingdao in Shandong province, while three more centers are currently under construction. As 2025 marks the company's 20th anniversary in China, "we will further expand our investment", Zhang said. Francisco Veloso, dean of INSEAD business school, said he believes China is poised for long-term growth, led by innovation and entrepreneurship, despite macroeconomic headwinds and rising global uncertainties. - China Daily/ANN
Korea Herald
12-06-2025
- Health
- Korea Herald
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
SINGAPORE, June 12, 2025 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea. Findings show that despite strong optimism about artificial intelligence's (AI) potential to ease pressure on APAC's healthcare systems, trust and implementation concerns persist. "The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people." Worsening patient outcomes because of care delays call for accelerated AI adoption About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days. Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times. AI has the potential to transform care delivery and significantly improve patient outcomes across APAC. Workforce challenge and data burdens call for AI relief Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago. These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden. [1] About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented: Addressing AI concerns from HCPs and patients crucial for widespread adoption A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes. Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%). Trust key to transforming healthcare in APAC For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area. For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%). Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies. "It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems." For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips. About the Future Health Index 2025 The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at
Yahoo
12-06-2025
- Health
- Yahoo
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions Building trust among patients and healthcare professionals around AI key to driving wider adoption SINGAPORE, June 12, 2025 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea. Findings show that despite strong optimism about artificial intelligence's (AI) potential to ease pressure on APAC's healthcare systems, trust and implementation concerns persist. "The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people." Worsening patient outcomes because of care delays call for accelerated AI adoption About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days. Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times. AI has the potential to transform care delivery and significantly improve patient outcomes across APAC. 81% of healthcare professionals in APAC believe that digital health technologies, including AI and predictive analytics, will lead to a reduction in hospital admissions in the future. 86% of healthcare professionals anticipate that these technologies will decrease the need for acute or emergency medical procedures and interventions. 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions. Workforce challenge and data burdens call for AI relief Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago. These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden.[1] About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented: 45% worry about an expanding patient backlog 42% cite growing burnout from non-clinical tasks 40% worry about their inability to provide cutting-edge care Addressing AI concerns from HCPs and patients crucial for widespread adoption A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes. Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%). Trust key to transforming healthcare in APAC For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area. For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%). Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies. "It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems." For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips. About the Future Health Index 2025 The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at [1] Global strategy on human resources for health: workforce 2030. 2016 Geneva World Health Organization View original content to download multimedia: SOURCE Royal Philips Sign in to access your portfolio
Yahoo
05-06-2025
- Business
- Yahoo
Philips announces exchange ratio for 2024 dividend
June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election result was 41.4%, which is below the 50% maximum as adopted in the General Meeting of Shareholders and therefore shareholders will receive the dividend in accordance with their election. Delivery of new common shares, with settlement of fractions in cash, if required, and payment of the cash dividend will take place from June 6, 2025. Upon distribution, the total issued share capital will amount to EUR 192,584,026, representing 962,920,132 common shares. More information is available via this link. For further information, please contact:Michael FuchsPhilips Global External RelationsTel.: +31 6 1486 9261E-mail: Dorin DanuPhilips Investor RelationsTel.: +31 20 59 77055E-mail: About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statementsThis release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. Sign in to access your portfolio
Yahoo
04-06-2025
- Business
- Yahoo
Philips to repurchase up to 6 million shares to cover long-term incentive plans
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million. The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company's General Meeting of Shareholders on May 8, 2025. Philips expects to take delivery of the shares in 2027. Further details will be available via this link. For further information, please contact:Michael FuchsPhilips Global External RelationsTel.: +31 6 1486 9261E-mail: Dorin DanuPhilips Investor RelationsTel.: +31 20 59 77055E-mail: About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statementsThis release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
